Head-To-Head Contrast: Actinium Pharmaceuticals (NYSE:ATNM) versus Avenue Therapeutics (NASDAQ:ATXI)

Avenue Therapeutics (NASDAQ:ATXI) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Avenue Therapeutics and Actinium Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0	0	0	0	0.00
Actinium Pharmaceuticals	0	0	1	0	3.00

Actinium Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 210.08%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Avenue Therapeutics.

Profitability

This table compares Avenue Therapeutics and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Insider & Institutional Ownership

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Avenue Therapeutics and Actinium Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38 million	$0.76	0.38
Actinium Pharmaceuticals	$90,000.00	447.14	-$48.82 million	($1.10)	-1.17

Avenue Therapeutics has higher earnings, but lower revenue than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Avenue Therapeutics has a beta of -0.51, suggesting that its stock price is 151% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500.

Summary

Actinium Pharmaceuticals beats Avenue Therapeutics on 8 of the 12 factors compared between the two stocks.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.